SMS Lifesciences India Limited has informed regarding Completion of ANVISA inspection at the manufacturing facility (Unit-1) in Hyderabad.
HALEOSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Haleos Labs Limited (formerly SMS Lifesciences India Limited) has successfully completed an inspection by the Brazilian Health Authority (ANVISA) at its API manufacturing facility (Unit-1) located in Kazipally, Sanga Reddy District, Telangana. The inspection took place from September 22 to September 26, 2025. The company states that this successful inspection reaffirms its compliance with international quality standards and opens the door for entry into Brazil, described as the largest pharmaceutical market in South America. The filing was made under SEBI Listing Regulations and also notes that the company name change to Haleos Labs Limited is currently being processed.
This is a positive development for shareholders as it clears a key regulatory hurdle for entering the Brazilian pharmaceutical market, which could open up a new revenue stream. The successful ANVISA audit enhances the company's credibility on international quality standards and supports future export growth, though actual revenue impact will depend on subsequent product approvals and commercial launches.